Reading KRRO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KRRO free→Reading KRRO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KRRO free→QuarterlyIQ Insights · KRRO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, Korro Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Results of Operations and Financial Condition. On March 12, 2026, Korro Bio, Inc. issued a press release announcing its financial results for the year ended December 31, 2025. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Entry into a Material Definitive Agreement Subscription Agreement On March 9, 2026, Korro Bio, Inc., or Korro, entered into a subscription agreement with a number of institutional accredited investors pursuant to which it agreed to sell and issue in a private placement pursuant to the exemption in Section 4(a)(2) of the Securities Act of 1933, as amended, or the 1933 Act: (i) an aggregate of 4,501,928 shares of its common stock, par value $0.001 per share at a purchase price of $11.11 per sha…
Unregistered Shares of Equity Securities To the extent required by this Item, the information included in
Regulation FD Disclosure On March 9, 2026, Korro issued a press release announcing the private placement, which is attached as Exhibit 99.1 to this current report on Form 8-K and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the 193…
Results of Operations and Financial Condition Korro expects to report that it had cash, cash equivalents and marketable securities of approximately $85.2 million as of December 31, 2025. The estimated cash figure is preliminary and unaudited, represents a management estimate as of the date of this current report on Form 8-K and is subject to completion of Korro’s financial closing procedures. Korro’s independent registered public accounting firm has not conducted an audit or review of, and do…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective December 15, 2025, Korro Bio, Inc., or Korro, entered into an amended and restated employment agreement with Jeffrey Cerio, which amended and restated his employment agreement dated August 28, 2024. Dr. Cerio’s new employment agreement is substantially consistent with the terms of his prior employment agreement as described in Korro’s def…
Results of Operations and Financial Condition. On November 12, 2025, Korro issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Entry into a Material Definitive Agreement. Effective November 11, 2025, Korro Bio, Inc., or Korro, and Novo Nordisk A/S, or Novo Nordisk, entered into an amendment of that certain research collaboration and license agreement dated September 13, 2024 pursuant to which Korro granted Novo Nordisk an exclusive worldwide license under certain intellectual property rights to research, develop, manufacture, commercialize or otherwise exploit certain licensed compounds and licensed products for an i…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 7, 2025, Olukemi A. Olugemo, M.D., FAAN resigned from her position of Chief Medical Officer of Korro to pursue another opportunity, effective November 12, 2025. In order to ensure the smooth transition of her functions, Dr. Olugemo has agreed to be available to serve as an advisor for three months following her resignation date. The boa…
Costs Associated with Exit or Disposal Activities. On November 12, 2025, Korro implemented a strategic restructuring to extend cash runway, including a workforce reduction of approximately 34%. Korro estimates that it will incur one-time restructuring charges of approximately $2.4 million including employee severance, benefits and related termination costs, the majority of which Korro expects to recognize during the three months ended December 31, 2025. The charges Korro expects to incur in c…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer On October 7, 2025, Vineet Agarwal announced his intention to resign from his position of Chief Financial Officer of Korro Bio, Inc., or Korro, effective October 17, 2025 to pursue another opportunity. In order to ensure the smooth transition of his functions, Mr. Agarwal has agreed to be available to serve as a…
Results of Operations and Financial Condition. On August 12, 2025, Korro Bio, Inc., or Korro, issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Costs Associated with Exit or Disposal Activities. On May 7, 2025, Korro initiated a strategic plan to streamline its operations, including a workforce reduction of approximately 20%. Korro estimates that it will incur one-time restructuring charges of approximately $1.2 million including employee severance, benefits and related termination costs, the majority of which Korro expects to recognize during the three months ended June 30, 2025. The charges Korro expects to incur in connection with…
Results of Operations and Financial Condition. On May 7, 2025, Korro Bio, Inc., or Korro, issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective March 27, 2025, Vineet Agarwal, Chief Financial Officer of Korro Bio, Inc., or the Company, ended his temporary medical leave of absence, which had been in effect since February 11, 2025. In connection with Mr. Agarwal’s return from a temporary medical leave of absence and the resumption of his duties and responsibilities as the Company’s…
Results of Operations and Financial Condition. On March 18, 2025, Korro Bio, Inc. issued a press release announcing its financial results for the year ended December 31, 2024. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or th…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., or Korro, is taking a temporary medical leave of absence. Accordingly, effective from February 11, 2025, Korro’s Board of Directors appointed Dr. Ram Aiyar, President and Chief Executive Officer (pr…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'expensive' to 'full'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.